NFE2L2 and non-small cell lung carcinoma: Arbour et al. analyzed co-occurring the genetic alterations of 330 patients with KRAS-mutant NSCLC by NGS and found that KEAP1-NRF2 alterations occurred in 27% of the patients that had shorter OS from the initiation of immunotherapy [23].